Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...
The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...
The Print on MSN2d
Top pharma alliance refutes ‘ill-researched’ US study linking Indian generics to higher adverse eventsIndian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...
A study linking Indian-made generic drugs to a higher risk of serious side effects in the US has drawn backlash from the industry’s most influential lobby group, as India moves to defend its dominant ...
Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.
Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...
India's Apollo Hospitals will invest more in artificial intelligence tools to ease the workload for its doctors and nurses by automating routine tasks, including medical documentation, a top executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback